Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00072722 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene Corporation